Cited by 76AI in cancer detectionRadiomics and Machine Learning in Medical ImagingArtificial Intelligence in Healthcare and Education

Artificial intelligence for prostate MRI: open datasets, available applications, and grand challenges

Open access
Sunoqrot, Mohammed R. S., Saha, Anindo, Hosseinzadeh, Matin, Elschot, Mattijs, Huisman, Henkjan·2022·European Radiology Experimental

Abstract

Artificial intelligence (AI) for prostate magnetic resonance imaging (MRI) is starting to play a clinical role for prostate cancer (PCa) patients. AI-assisted reading is feasible, allowing workflow reduction. A total of 3,369 multi-vendor prostate MRI cases are available in open datasets, acquired from 2003 to 2021 in Europe or USA at 3 T (n = 3,018; 89.6%) or 1.5 T (n = 296; 8.8%), 346 cases scanned with endorectal coil (10.3%), 3,023 (89.7%) with phased-array surface coils; 412 collected for anatomical segmentation tasks, 3,096 for PCa detection/classification; for 2,240 cases lesions delineation is available and 56 cases have matching histopathologic images; for 2,620 cases the PSA level is provided; the total size of all open datasets amounts to approximately 253 GB. Of note, quality of annotations provided per dataset highly differ and attention must be paid when using these datasets (e.g., data overlap). Seven grand challenges and commercial applications from eleven vendors are here considered. Few small studies provided prospective validation. More work is needed, in particular validation on large-scale multi-institutional, well-curated public datasets to test general applicability. Moreover, AI needs to be explored for clinical stages other than detection/characterization (e.g., follow-up, prognosis, interventions, and focal treatment).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s41747-022-00288-8

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sunoqrot, M. R. S., Saha, A., Hosseinzadeh, M., Elschot, M., & Huisman, H.
Affiliations
  • Norwegian University of Science and Technology (NO)
  • Radboud University Medical Center (NL)
Corresponding author
Sunoqrot, Mohammed R. S.
Venue
European Radiology Experimental
Published
2022-08-01
Volume
6
Issue
1
Pages
35-35
ISSN
2509-9280 (ISSN-L)
OpenAlex
W4289100949
Cited by
76
References
66
Citations by year
2026: 13 · 2025: 25 · 2024: 14 · 2023: 20 · 2022: 4
FWCI
1.11
Type
journal article
Language
en
Open access
Locations
  • European Radiology Experimental (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
  • The Research Council of Norway (295013)
  • The Norwegian Cancer Society and Prostatakreftforeningen (215951)
  • The Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology (90265300, 90793700)
  • EU H2020 ProCAncer-I (952159, Number)
  • EU H2020 PANCAIM (101016851)
  • EU IMI2 PIONEE (777492)
  • EU IMI2 PIONEER (777492)
  • NTNU Norwegian University of Science and Technology
Topics
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
Keywords
artificial intelligence, prostate MRI, prostate cancer, AI-assisted reading, prostate cancer detection, prostate cancer classification, lesion delineation, anatomical segmentation, annotation quality, multi-institutional validation, societal challenges, focal therapy, prostate-specific antigen
MeSH terms
Artificial Intelligence, Humans, Magnetic Resonance Imaging, Male, Prostate, Prostatic Neoplasms, Sensitivity and Specificity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review